Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab

Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab

Abstract Introduction Durvalumab after concurrent chemoradiation (cCRT) is now standard of care for unresected stage III non–small cell lung cancer (NSCLC). However, there is limited data on radiation pneumonitis (RP) with this regimen. Therefore, we assessed RP and evaluated previously validated to...

Full description

Bibliographic Details
Main Authors: Narek Shaverdian, Maria Thor, Annemarie F. Shepherd, Michael D. Offin, Andrew Jackson, Abraham J. Wu, Daphna Y. Gelblum, Ellen D. Yorke, Charles B. Simone II, Jamie E. Chaft, Matthew D. Hellmann, Daniel R. Gomez, Andreas Rimner, Joseph O. Deasy
Format: Article
Language:English
Published: Wiley 2020-07-01
Series:Cancer Medicine
Subjects:
durvalumab
non–small cell lung cancer
radiation pneumonitis
Online Access:https://doi.org/10.1002/cam4.3113

Internet

https://doi.org/10.1002/cam4.3113

Similar Items